MRMarie-Laure Raffin-Sanson

Marie-Laure Raffin-Sanson

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Marie-Laure Raffin-Sanson has a total of 113 co-authors. Here are the top co-authors by number of shared publications:

  • Laure Cazabat

    Department of Endocrinology and Nutrition, Ambroise Paré Universitary Hospital, Assistance Publique Hôpitaux de Paris, Boulogne, France

    4 shared publications
  • Jérôme Bertherat

    Université Paris Cité, CNRS, Inserm, Institut Cochin, Paris, France

    3 shared publications
  • Mirella Hage

    Department of Endocrinology, Diabetology and Nutrition, Hôpital Ambroise Paré, Assistance Publique-Hôpitaux de Paris , Boulogne-Billancourt 92100

    3 shared publications
  • Ramona Zaharia

    Department of Endocrinology and Nutrition, Ambroise Paré Universitary Hospital, Assistance Publique Hôpitaux de Paris, Boulogne, France

    3 shared publications
  • Rossella Libé

    Department of Endocrinology, Cochin Hospital, Assistance Publique Hôpitaux de Paris, Paris Descartes University, Paris, France

    3 shared publications
  • C. De Marcellus

    Service d’Endocrinologie Nutrition, Hôpital Ambroise Paré, AP–HP, Boulogne Billancourt, France

    2 shared publications

Latest Publications

  • A suggested protocol for the endocrine postoperative management of patients undergoing pituitary surgery

    by Fatima Zarzour, Mirella Hage, Marie-Laure Raffin Sanson, Bertrand Baussart, Marlene Chakhtoura


  • Nutritional Status of Vegetarian Patients Before and After Bariatric Surgery: a Monocentric Retrospective Observational Case–Control Study

    by Aurélie Phan, Mirella Hage, Ramona Zaharia, Marie Vigan, Séverine Coursault, Sandy Wilson, Elodie Gabali, Loic Foussier, Karina Vychnevskaia, Marie-Laure Raffin-Sanson, et al.

    The obesity pandemic is associated with an increasing number of bariatric surgeries which allow improvement in obesity-related comorbidities and life expec


  • Editorial

    by Marie Laure Raffin Samson, Yves Reznik

  • Complications Requiring Intensive Nutritional Care After Bariatric Surgery Result in More Long-Term Weight Loss but Has No Impact on Nutritional Deficiencies and Depression-Anxiety Scores

    by Marion Bretault, Ramona Zaharia, Marie Vigan, Karina Vychnevskaia, Marie-Laure Raffin-Sanson, Pascal Crenn, Mirella Hage

    Purpose Bariatric surgery is associated with significant weight loss and improvement in comorbid conditions but in rare cases can expose to complications requiring intensive nutritional care (INC). INC in this context is poorly described and no data are available concerning long-term impact. Materials and Methods We retrospectively reviewed charts of bariatric patients who were hospitalized in our institution between 2013 and 2018. We identified patients with a postoperative complication requiring INC and we described their nutritional management (INC group). These patients were compared with controls matched to age, gender, preoperative BMI, and type of surgery selected from our database (control group). The primary endpoint was the percentage of total weight loss (%TWL) at 2.5 years. Secondary endpoints were improvement of co-morbidities, vitamin deficiencies, and depression/anxiety scores. Results The INC group consisted of 18 patients among which 77.8% had sleeve gastrectomy (SG). Half of these patients underwent revisional surgery. The most common complication was fistula formation (66.7%). Patients in the INC group, compared to the control group, showed a significantly higher %TWL at 2.5 years (33.6% vs 26.1%, P = 0.03). There was no significant difference in either reduction of preoperative comorbidities or depression/anxiety scores between the two groups. The number of patients with more than three nutritional deficiencies was similar in both groups. Thiamine deficiency was only observed in the INC group. Conclusion Complications requiring INC after bariatric surgery occur mainly after revisional surgery and may increase long-term %TWL but have no impact on nutritional deficiencies or symptoms of anxiety/depression. Graphical abstract


  • Méningiomes et progestatifs

    by M.L. Raffin-Sanson, C. Birzu, I. Lemaire-Martin, M. Peyre, S. Gaillard, C. De Marcellus, F. Bielle, C. Villa, A. Boch, H. Loiseau, et al.

  • Coexistence of Autoimmune Hyper- and Hypothyroidism in a Kindred with Reduced Sensitivity to Thyroid Hormone

    by Yasmine Abdellaoui, Dimitra Magkou, Sofia Bakopoulou, Ramona Zaharia, Marie-Laure Raffin-Sanson, Laure Cazabat

    Introduction: Resistance to thyroid hormone beta (RTHβ) is a rare disease with an autosomal dominant transmission. Diagnosis may be challenging especially in patients with hyper- or hypothyroidism. Case Presentation: A 31-year-old male patient with suppressed thyroid-stimulating hormone (TSH), elevated free thyroxine and free triiodothyronine, along with high thyroid receptor antibodies was diagnosed with Graves’ disease. Benzylthiouracil was started. One month later, reduced sensitivity to thyroid hormones was suspected because of persistently high thyroid hormone levels contrasting with high TSH level. Molecular analysis highlighted a 10c.1357C>T p.P453S mutation in the thyroid hormone receptor beta gene (THRB). RTHβ was diagnosed. Several relatives also had RTHβ (the mother, the young son, and 2 out of 3 siblings). Autoimmune hypothyroidism was present in the mother, whereas 2 out of 3 siblings had asymptomatic autoimmunity. Discussion/Conclusion: Both Graves’ disease and autoimmune hypothyroidism were described in patients with RTHβ. We show here for the first time that autoimmune hypo- and hyperthyroidism may coexist in kindred with RTHβ. Seven previously published cases of Graves’ disease and RTHβ were retrieved and analyzed. Treatments and thyroid hormone level targets are discussed as well as the possible link between RTHβ and autoimmune thyroid diseases.


  • Laparoscopic Revision of Bariatric Surgeries in Two Patients with Severe Resistant Hypocalcemia After Endocrine Cervical Surgery

    by Magda Zaarour, Ramona Zaharia, Marion Bretault, Christel Jublanc, Capucine De Marcellus, Jean-Luc Bouillot, Hervé Lefebvre, Jean-Michel Oppert, Judith Aron-Wisnewsky, Marie-Laure Raffin-Sanson

    Severe hypocalcemia complicating cervical endocrine surgery in patients with gastric bypass can constitute a major concern. When usual therapies fail to maintain calcemia within the normal range without secondary adverse events, reversal of the bariatric surgery should be considered. We herein report the outcomes of laparoscopic revision of bariatric surgeries in two patients suffering from severe resistant hypocalcemia following cervical surgery, requiring in one case recombinant PTH administration and, in the other, daily intravenous calcium injections. The Roux-en-Y gastric bypass was switched to sleeve gastrectomy in the first patient, and in the second patient, the biliopancreatic diversion with duodenal switch was revised, to restore the upper and distal parts of the alimentary tract. Rapid improvement of hypocalcemia was observed in both cases.


  • Foetal exposure to mitotane/Op'DDD: Post‐natal study of four children

    by Dimitra Magkou, Christine Do Cao, Claire Bouvattier, Claire Douillard, Capucine de Marcellus, Laure Cazabat, Maxime Gérard, Marie‐Laure Raffin‐Sanson, Jacques Young

    Objective: Mitotane/Op'DDD is used in the treatment of adrenocortical carcinoma and for other causes of hypercortisolism. Mitotane inhibits cortisol secretion and displays adrenolytic and antitumor actions. This compound is a metabolite of the pesticide and endocrine disruptor DDT (dichlorodiphenyltrichloroethane) and is classified among teratogenic compounds worldwide. However, little is known about its effects on human development.Design: The outcome of four children exposed to mitotane during their intrauterine life was examined.Patients: Patients having conceived while taking mitotane, or with detectable mitotane plasma levels, were retrospectively recruited via the French COMETE and FIRENDO networks.Measurements: Mitotane in maternal plasma, adrenocortical hormones in children.Results: Three women treated with mitotane gave birth to four children. During early pregnancy, all patients had detectable mitotane plasma levels (0.9, 2.4 and 6.7 mg/L, respectively). During pregnancy, no foetal malformations were detected. The four exposed newborns presented at birth with apparently normal adrenal function and genitalia. One twin female had a low birthweight. Evaluation at birth and after 3 months, 2 years and 7 years of follow‐up showed no significant neurological abnormality. Evaluation of adrenocortical functions showed no cortisol deficiency.Conclusions: Unexpectedly, exposure of these four children to mitotane during foetal life seemed to have no clear teratogenic effect. However, considering the sub‐therapeutic mitotane concentrations used here, the small number of cases, and because long‐term follow‐up is unknown, we strongly advise not to take mitotane during pregnancy and still recommend avoiding pregnancy, at least as long as mitotane plasma levels remain detectable.


  • Group 2: Adrenal insufficiency: screening methods and confirmation of diagnosis

    by Philippe Chanson, Laurence Guignat, Bernard Goichot, Olivier Chabre, Dinane Samara Boustani, Rachel Reynaud, Dominique Simon, Antoine Tabarin, Damien Gruson, Yves Reznik, et al.


  • Grossesse et mitotane/OP’DDD : étude en post-natal de 4 enfants exposés pendant la période fœtale

    by D. Magkou, C. Do Cao, C. Bouvattier, C. Douillard, C. De Marcellus, L. Cazabat, M.L. Raffin-Sanson, J. Young